{"analyses":[{"ciLowerLimit":"1.50","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.06","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0016","paramType":"Odds Ratio (OR)","paramValue":"3.57","statisticalComment":"P-value was calculated using stratified exact Cochran-Mantel-Haenszel test by adjusting for the WBC/platelet status (abnormal vs normal) at baseline.","statisticalMethod":"Exact Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.1","upperLimit":"32.7","value":"23.6"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"14.7","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"Complete Hematological Remission at Week 32 was defined as any participant who achieved hematocrit control with a platelet count less than or equal to 400 X 10\\^9/L and a white blood cell count less than or equal to 10 X 10\\^9/L.","dispersionType":"95% Confidence Interval","groups":[{"description":"Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.","id":"OG001","title":"Best Available Therapy"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) comprises all participants to whom study treatment had been assigned by randomization.","reportingStatus":"POSTED","timeFrame":"32 Weeks","title":"The Percentage of Participants Achieving Complete Hematological Remission at Week 32","type":"SECONDARY","unitOfMeasure":"percentage of participants"}